You are here

Herbert Smith Freehills advises on Shanghai HeartCare Medical's HK$1.13 billion Hong Kong IPO 史密夫斐尔律师事务所为心玮医疗11.3亿港元IPO提供法律服务

20 August 2021 | China
News

Share

Leading global law firm Herbert Smith Freehills has advised neuro-interventional medical device manufacturer Shanghai HeartCare Medial Technology Corporation Limited (06609.HK) on its mainboard listing on the Stock Exchange of Hong Kong.

Shanghai HeartCare Medical focuses on reducing the mortality rate and improving the prognosis of stroke. Since founding in 2016, the company has commercialised four products and has a total of 19 approved products and product candidates covering all major stroke subtypes and surgical pathways in the neuro-interventional field, with ischemic stroke prevention product candidates to capture demand from the cardiac market.

The IPO raised approximately HK$1.13billion (US$143 million), and listed on 20 August 2021.

"We are delighted to have worked with Shanghai HeartCare Medical, one of the leading neuro-interventional medical device manufacturers on its successful listing on the HKEx," said Beijing partner Zhong Wang. "Domestic players are becoming increasingly important in addressing unmet medical needs in China. The ability to develop advanced products with features tailored to the needs of Chinese patients and physicians is expected to be one of the key distinguishing factors for successful competition in this market."

Herbert Smith Freehills has advised on a number of biotech listings since the Hong Kong exchange introduced its new regime for biotech listings in 2018, including those by Shanghai Junshi Biosciences (01877.HK), TOT BIOPHARM (01875.HK), SinoMab Bioscience Limited (03681.HK), Peijia Medical (09996.HK), Antengene Corporation Limited (06996.HK), CARsgen Therapeutics (02171.HK), and Brii Biosciences (02137.HK).

"We have longstanding experience of advising fundraisings in international capital markets and a robust record of working with healthcare clients,” said Beijing office partner Isaac Chen. "We congratulate Shanghai HeartCare Medical on this IPO and look forward to the company's continued success."

The ischemic stroke neuro-interventional device market in China increased from RMB381.1 million in 2015 to RMB1.9 billion in 2019 at a CAGR of 49.7%, and is expected to further increase to RMB25.4 billion in 2030 at a CAGR of 26.5% from 2019 to 2030.

Zhong and Isaac jointly led the team advising the issuer, assisted by senior associate Sherry Lai in Hong Kong, associates Kathy Zhang, Yuchen Zhu, Robert Li and Bryan Zhu, and legal assistants Yuanyuan Yin, Ted Zhang, Emma Chen and Aiye Jia in Beijing. London-based partner and head of US Securities Tom O'Neil and Hong Kong-based of counsel George Wu provided US securities law advice.

Associate director Lucy Yao led Herbert Smith Freehills Kewei Joint Operation’s Alternative Legal Services business to provide high-efficiency solutions for verification and other document-intensive processes during the offering, assisted by senior lawyer Helen Liang, legal specialist Selina Wang and legal analyst Shawna Peng.

全球领先的律师事务所史密夫斐尔作为神经介入医疗器械公司(06609.HK)的境外律师,为其在香港联交所主板上市提供法律服务。

心玮医疗致力于降低脑卒中死亡率并改善预后。公司成立于2016年,拥有4款商业化产品和19款在研产品,覆盖了神经介入领域的所有主要脑卒中亚型及手术路径,并且公司的缺血性脑卒中预防在研产品有助于满足心脏病市场的需求。

心玮医疗在首次公开募股中融资超过11.3亿港元(约合1.43亿美元),于2021年8月20日开始在香港联交所交易。

史密夫斐尔北京办公室合伙人王重(Zhong Wang)表示:“心玮医疗是领先的神经介入医疗器械公司,我们非常荣幸为心玮医疗在港交所上市提供助力。在满足国内医疗器械市场的需求缺口方面,中国企业正在发挥越来越重要的作用。能够推出符合中国患者和医疗需求的产品,将是在这个市场成功的关键因素之一。”

自港交所于2018年放宽生物技术公司上市条件以来,史密夫斐尔已为多家公司在港上市提供法律服务,包括君实生物(01877.HK)、东曜药业(01875.HK)、中国抗体(03681.HK)、沛嘉医疗(09996.HK)、德琪医药(06996.HK)、科济药业(02171.HK)和腾盛博药(02137.HK)。

北京办公室合伙人陈敏(Isaac Chen)表示:“史密夫斐尔长期助力客户在国际资本市场融资,在为医疗行业客户提供法律服务方面经验丰富。衷心向心玮医疗此次IPO表示祝贺,并期待公司继续取得成功。”

中国缺血性卒中神经介入医疗器械场从2015年的3.811亿元人民币增长到2019年的19亿元人民币,复合年均增长率为49.7%,预计2019年至2030年将以26.5%的复合年均增长率进一步增长至254亿元人民币。

合伙人王重和陈敏率领律师团队为此次上市发行人提供法律服务。主要团队成员包括香港办公室黎翠芬(Senior Associate)、北京办公室张凯西(Associate)、朱雨辰(Associate)、李超(Associate)、朱步凡(Associate)、尹圆圆(Legal Assistant)、张刚(Legal Assistant)、陈阿婷(Legal Assistant)和贾瑷烨(Legal Assistant)。伦敦办公室合伙人、美国证券法主管合伙人Tom O'Neil 以及香港办公室资深顾问吴卓人就该笔交易的美国证券方面事宜提供咨询。

联营办公室替代性法律服务(ALT)联合团队在发行期间为招股书验证及其他文件密集型工作提供高效率的解决方案,主要成员包括梁琳(Senior Lawyer)、王思颖(Legal Specialist)和彭祺程(Legal Analyst)。

 

See how we help our clients in

Equity Capital Markets

Learn More

Key Contacts

Media Contact

For further information on this news article, please contact:

Sally Greig, Head of Communications, Asia

Hong Kong
Tel: 
+852 21014624

VIVIAN HUANG, COMMUNICATIONS MANAGER, CHINA

Beijing
Tel: 
+86 10 65355025